Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma

Wu, Hao; Liu, Jialin; Wang, Zhifei; Yuan, Wen; Chen, Ling

doi:10.1111/cns.13714

Cited by 33 publications

(27 citation statements)

References 141 publications

(266 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioblastoma (GBM), the WHO grade IV glioma, is the most common and fatal type of primary brain cancer. 1 , 2 , 3 Although multimodal treatments are available, including surgical resection, chemotherapy, and radiotherapy, the median survival of patients remains less than 16 months. 4 , 5 The tumor microenvironment plays a pivotal role in supporting malignant growth and progression.…”

Section: Introductionmentioning

confidence: 99%

Hypoxia‐induced polypoid giant cancer cells in glioma promote the transformation of tumor‐associated macrophages to a tumor‐supportive phenotype

Liu

Shi

et al. 2022

CNS Neurosci Ther

Self Cite

View full text Add to dashboard Cite

Aims: Polypoid giant cancer cells (PGCCs) represent a unique subgroup of stem-like cells, acting as a critical factor in promoting the recurrence of various solid tumors.The effect of PGCCs on the tumor malignancy of glioma and its immune microenvironment remains unclear.Methods: Bioinformatic analysis was performed to investigate the relationship between M2 tumor-associated macrophages (TAMs) infiltration and survival of glioblastoma (GBM) patients. The spatial location of M2 TAMs in GBM was also investigated using the Ivy Glioblastoma Atlas Project (Ivy GAP) database. PGCCs were quantified in glioma of different grades. CoCl 2 was used to induce PGCCs in cultures of A172 cells. PGCCs, and their progeny cells in cultures were further evaluated for morphological features, tumorsphere formation, and TAMs activation. Results:The magnitude of M2 TAMs infiltration is significantly correlated with poor survival in GBM patients. M2 TAMs were enriched in the perinecrotic zone (PNZ) of GBM and positively correlated with hypoxic levels. Increased PGCCs were detected in glioma specimens of higher grades. CoCl 2 induced hypoxia and the transformation of A172 cultures into PGCCs, producing the progeny cells, PGCCs-Dau, through asymmetric division. PGCCs and PGCCs-Dau possessed tumor stem cell-like features, while PGCCs-Dau enhanced the polarization of TAMs into an M2 phenotype with relevance to immunosuppression and malignancy in GBM. Conclusions:PGCCs promote malignancy and immune-suppressive microenvironment in GBM. PGCCs or their progeny cells may be a potential therapeutic target for GBM.

show abstract

Section: Introductionmentioning

confidence: 99%

Hypoxia‐induced polypoid giant cancer cells in glioma promote the transformation of tumor‐associated macrophages to a tumor‐supportive phenotype

Liu

Shi

et al. 2022

CNS Neurosci Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, clinical trials have not shown significant benefit in OS and PFS. Different target checkpoint inhibitors continue to be investigated, including CD47, CD24, CD37 (NCT02658981), LAG-3, and TIGIT/CD96 [83,84]. Additionally, combination with different immunotherapy strategies may be a future direction for CPI research.…”

Section: Nivolumabmentioning

confidence: 99%

Glioblastoma Treatment: State-of-the-Art and Future Perspectives

Camacho

Flores-Vázquez

Moscardini-Martelli

et al. 2022

IJMS

View full text Add to dashboard Cite

(1) Background: Glioblastoma is the most frequent and lethal primary tumor of the central nervous system. Through many years, research has brought various advances in glioblastoma treatment. At this time, glioblastoma management is based on maximal safe surgical resection, radiotherapy, and chemotherapy with temozolomide. Recently, bevacizumab has been added to the treatment arsenal for the recurrent scenario. Nevertheless, patients with glioblastoma still have a poor prognosis. Therefore, many efforts are being made in different clinical research areas to find a new alternative to improve overall survival, free-progression survival, and life quality in glioblastoma patients. (2) Methods: Our objective is to recap the actual state-of-the-art in glioblastoma treatment, resume the actual research and future perspectives on immunotherapy, as well as the new synthetic molecules and natural compounds that represent potential future therapies at preclinical stages. (3) Conclusions: Despite the great efforts in therapeutic research, glioblastoma management has suffered minimal changes, and the prognosis remains poor. Combined therapeutic strategies and delivery methods, including immunotherapy, synthetic molecules, natural compounds, and glioblastoma stem cell inhibition, may potentiate the standard of care therapy and represent the next step in glioblastoma management research.

show abstract

“…These findings suggest that regulating efferocytosis function may be an alternative treatment strategy ( Gjorgjevski et al, 2019 ). In addition, studies have demonstrated that GBM is closely related to the overexpression of the “do not eat me” signal CD47, which allows the cells to escape efferocytosis ( Hu et al, 2020 ; Wu et al, 2021b ).…”

Section: Nervous System Diseases Related To Efferocytosismentioning

confidence: 99%

Efferocytosis in the Central Nervous System

Zhao

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The effective clearance of apoptotic cells is essential for maintaining central nervous system (CNS) homeostasis and restoring homeostasis after injury. In most cases of physiological apoptotic cell death, efferocytosis prevents inflammation and other pathological conditions. When apoptotic cells are not effectively cleared, destruction of the integrity of the apoptotic cell membrane integrity, leakage of intracellular contents, and secondary necrosis may occur. Efferocytosis is the mechanism by which efferocytes quickly remove apoptotic cells from tissues before they undergo secondary necrosis. Cells with efferocytosis functions, mainly microglia, help to eliminate apoptotic cells from the CNS. Here, we discuss the impacts of efferocytosis on homeostasis, the mechanism of efferocytosis, the associations of efferocytosis failure and CNS diseases, and the current clinical applications of efferocytosis. We also identify efferocytosis as a novel potential target for exploring the causes and treatments of CNS diseases.

show abstract

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma

Cited by 33 publications

References 141 publications

Hypoxia‐induced polypoid giant cancer cells in glioma promote the transformation of tumor‐associated macrophages to a tumor‐supportive phenotype

Hypoxia‐induced polypoid giant cancer cells in glioma promote the transformation of tumor‐associated macrophages to a tumor‐supportive phenotype

Glioblastoma Treatment: State-of-the-Art and Future Perspectives

Efferocytosis in the Central Nervous System

Contact Info

Product

Resources

About